Regular Treatment Strategy with a Large Amount of Carvedilol for Heart Failure Improves Biventricular Systolic Failure in a Patient with Repaired Tetralogy of Fallot

• DOI: 10.1536/ihj.17-525
• Publication Date: 2018-08-10T22:26:28Z
• Authors: Katsura Soma; Atsushi Yao; Akihito Saito; Toshiro Inaba; Yuichi Ishikawa; Yasutaka Hirata; Issei Komuro
• Keywords: Heart Failure; Male; Systole; Adrenergic beta-Antagonists; Carbazoles; Middle Aged; Magnetic Resonance Imaging; 3. Good health; Propanolamines; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Tetralogy of Fallot; Ventricular Function, Right; Humans; Carvedilol; Heart Failure, Systolic

It is widely known that β-blockers exert beneficial effects on non-ischemic and ischemic systolic heart failure (sHF) in nonstructural hearts. However, whether β-blockers exert similar effects on sHF associated with congenital heart disease (CHD), particularly in an anatomical right ventricle, remains under debate.Here we report the case of an adult man with repaired tetralogy of Fallot suffering from biventricular heart failure. Treatment with carvedilol directly improved the systolic function of the right and left ventricles. This case report strongly suggests there is potential for carvedilol to exert a beneficial effect on heart failure in CHD. The appropriate titration of carvedilol and patient follow-up for long-term effects are important when treating adult patients with CHD with β-blockers.